![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 43, 30337-30340, October 22, 1999
From the Department of Biochemistry and Molecular Biology, Louisiana State University Medical Center, Shreveport, Louisiana 71130-3932
The last several years have witnessed an
explosion in the published literature on two topics, the pathways that
transduce extracellular signals to their intracellular targets and
modification of the core translational apparatus in response to these
signals. Most of these pathways result in cell growth and cell
division. Synthesis of the entire complement of proteins is necessary
to double the cell size, but synthesis of the so-called
"growth-regulated" proteins (1) is needed for cell division. This
article summarizes recent advances in our understanding of how a single
mitogenic stimulus can simultaneously lead to an increase in both
global and growth-regulated protein synthesis.
The three stages of protein synthesis are catalyzed by initiation,
elongation, and release factors (Ref. 2;
a guide to current and previous nomenclature can be found in Ref. 3). A
ternary complex of eIF2·GTP·Met-tRNAi1 binds to
the 40 S ribosomal subunit to form the 43 S initiation complex (Fig.
1). The eIF4 factors plus poly(A)-binding
protein recognize the 5'-terminal cap or 3'-terminal poly(A) tract of mRNA, unwind mRNA secondary structure, and transfer it to the 43 S
initiation complex, resulting in the 48 S initiation complex. Scanning
for the first initiation codon in good sequence context requires eIF4A
and the presence of eIF1 and eIF1A (4). Then eIF5 stimulates GTP
hydrolysis by eIF2, after which the initiation factors are replaced by
the 60 S subunit to form the 80 S initiation complex. The released
eIF2·GDP is recycled to eIF2·GTP by the GEF eIF2B. The first
elongator aminoacyl-tRNA is brought to the A-site by eEF1, followed by
a cycle of GTP hydrolysis and exchange analogous to that of eIF2.
Translocation is catalyzed by eEF2, again with a GTP hydrolysis
cycle.
RTKs--
The binding of growth factors to the extracellular
domain of RTKs causes a conformational change that induces
oligomerization and activation of the intracellular protein Tyr kinase
domain (Ref. 5; Fig. 2). Substrates for
the kinase can be either the RTK itself or a separate RKS. The SH2
domains of several different signaling molecules dock to the resulting
Tyr(P)s in a sequence-specific manner, thereby activating separate
downstream signaling cascades.
GPCR--
These receptors are coupled to heterotrimeric G-proteins
(6). Dissociation of the G-protein subunits activates AC, PLC, and
other downstream effectors. PLC hydrolyzes PtdIns(4,5)P2 to DAG and Ins(1,4,5)P3.
RKS--
These are docking proteins for downstream effectors of
RTKs (7). The best studied RKS are the insulin receptor substrates, which include IRS-1, IRS-2, IRS-3, Gab-1, and p62DOK.
Members of the IRS family bind to insulin receptor via an
NH2-terminal PH domain and a Tyr(P)-binding domain. The
COOH-terminal portions of the proteins contain numerous Tyr
phosphorylation sites. IRS-1 alone provides docking sites for PI3-K,
SH-PTP2, Grb-2, Fyn, Nck, and Crk.
SH-PTP2--
This phosphatase contains two SH2 domains, and enzyme
activity is maximally activated when both are occupied by
Tyr(P)-containing peptides (8). SH-PTP2 is activated by docking to EGF
receptor, platelet-derived growth factor receptor, c-kit,
insulin receptor, IRS-1, IRS-2, and IRS-3 and may serve to attenuate
the Tyr(P) signal in these molecules (7).
Ras--
This G-protein is bound to the plasma membrane by
COOH-terminal prenylation and myristoylation (9). GEF activity is
provided by SOS, which associates constitutively with the SH2- and
SH3-containing protein Grb-2. The Grb-2·SOS complex is recruited to
the plasma membrane by binding to specific Tyr(P)s in IRS-1, IRS-2,
Shc, or SH-PTP2 (7). Another GEF, Ras-GEF, is stimulated by
Ca2+/calmodulin (CaM) downstream of GPCR (10). The
hydrolysis of GTP by Ras is stimulated by GTPase-activating proteins
such as p120GAP and NF1 (9).
MAPKs--
Ras·GTP activates the Ser/Thr kinase Raf-1 by
recruiting it to the plasma membrane. Raf-1, in turn, phosphorylates
and activates MEK1 and MEK2. The MEKs are dual specificity kinases,
phosphorylating both Thr and Tyr residues in ERK1 and ERK2 (p42 and
p44 MAPKs).
PI3-K--
This kinase is composed of a catalytic subunit and a
SH2-containing regulatory subunit that binds to Tyr(P)s in RTKs and RKS (7). PI3-K is also activated synergistically by direct binding to
Ras·GTP (11). PI3-K is a dual specificity kinase that phosphorylates PtdIns at the 3-position and proteins on Ser/Thr residues (12). The
lipid phosphorylation signal activates PDK and PKB, and the protein
phosphorylation signal activates MAPK (13). Both activities are
inhibited by wortmannin and LY294002 (14).
PDKs--
These recently discovered kinases, with at least four
isoforms, bind to and are activated by PtdIns(3,4,5)P3 by
their COOH-terminal PH domains (15, 16).
PKB (Akt, RAC-PK)--
PKB exists in at least four isoforms ( PKC--
There are at least 10 isoforms of PKC ( Ca2+--
Changes in cytosolic Ca2+
levels can occur by at least two mechanisms (26). First, GPCR operate
Ca2+ channels that allow influx from the extracellular
space. Second, Ins(1,4,5)P3, released in response to both
RTKs and GPCR, binds to receptors in the endoplasmic reticulum and
releases Ca2+ into the cytosol.
GSK-3--
This kinase regulates numerous cellular processes
besides phosphorylation of glycogen synthase, including
insulin-stimulated protein synthesis (27). Phosphorylation of GSK-3 at
Ser-9 inactivates the enzyme and is correlated with the
activation of protein synthesis. GSK-3 is phosphorylated directly
by PKB in vivo (28, 29).
mTOR (FRAP, RAFT-1)--
mTOR is a 290-kDa protein kinase that is
activated by PKB (30) and phosphorylates Ser/Thr-Pro motifs (31). As
the name implies, its kinase activity is inhibited by the
immunosuppressant rapamycin (31). The ability of insulin to cause
phosphorylation and activation of mTOR is attenuated by cAMP (32).
Ribosomal S6 Kinases--
The major activity responsible for
phosphorylation of ribosomal protein S6 is p70S6K (33),
which is activated by hierarchical phosphorylation of seven Ser/Thr
sites. Phosphorylation of COOH-terminal sites occurs first, making
Thr-389 available for phosphorylation by a rapamycin-sensitive pathway
(34) and culminating in phosphorylation of Thr-229 by constitutively
active PDK1 (35). Multipotential S6 kinase is activated and becomes
membrane-associated in response to insulin (36). p90S6K is
activated in response to growth factors by forming complexes with ERK1
and -2 and undergoing phosphorylation (37). Additional S6 kinases
continue to be discovered (38, 39).
PHAS (4E-BP)--
PHAS-I was originally observed as a
phosphorylated protein that increased upon insulin treatment of cells
but was later found to bind eIF4E specifically (40). Two additional
isoforms have since been found, PHAS-II and PHAS-III (41).
Phosphorylation of PHAS occurs at six or more sites, two to five of
which appear to result from direct phosphorylation by mTOR (34,
42).
Mnk1 and -2--
These kinases, homologous to
p90S6K, were identified as binding partners of ERK1 and -2 (43) and in a screen for ERK1 substrates (44). Mnk is activated by
phosphorylation at Thr-197 and Thr-202 both by a mitogen-activated
pathway via ERK1 or -2 and also by a stress-activated pathway via p38
(45). Interestingly, Mnk1 also binds to the COOH terminus of eIF4G (45,
46).
eEF2K (CaMK III)--
This kinase is activated by
Ca2+/CaM and contains a putative CaM-binding domain
COOH-terminal to the catalytic domain (47). eEF2 kinase is also
activated by cAMP, independently of Ca2+ (48).
Two types of signal-induced modifications of translation factors
have been described to date: changing the intrinsic activity or binding
properties of the factor by phosphorylation and sequestration of the
factor in an inactive complex, the formation or dissociation of which
may be controlled by phosphorylation.
eIF2--
Most situations that lead to phosphorylation of eIF2 eIF2B--
This GEF is phosphorylated on the eIF4E--
The mRNA cap-binding protein is phosphorylated at
Ser-209 in vivo (54, 55) by Mnk1 and -2 (43, 45), resulting
in an increase of its affinity for caps (56). eIF4E variants unable to
bind eIF4G are poorly phosphorylated (46). The availability of eIF4E is
also regulated by formation of an inactive complex with PHAS, and
phosphorylation of PHAS causes dissociation of the complex (57, 58).
The relationship between these two eIF4E regulatory mechanisms is
unclear. In vitro, PHAS inhibits eIF4E phosphorylation by
Mnk1 (59), but in vivo, eIF4E is extensively phosphorylated
in cells overexpressing PHAS, suggesting that eIF4E phosphorylation is
independent of PHAS (45).
eIF4G--
This linking protein, as part of the eIF4F complex, is
phosphorylated at unknown sites by multipotential S6 kinase (60). The
phosphorylated complex is more stimulatory for in vitro
protein synthesis and binding of mRNA to the 43 S initiation complex.
S6--
This ribosomal protein is phosphorylated at five Ser
residues, located at 235, 236, 240, 244, and 247 (33). However, the effect of S6 phosphorylation on protein synthesis is unclear. There is
a correlation between activation of p70S6K and translation
of mRNAs containing a 5'-TOP tract (61), and treatment of 80 S
ribosomes with multipotential S6 kinase increases the rate of
elongation 2-fold (36). A recent study implicates S6 phosphorylation in
the interaction between 40 S subunits and mRNA (62).
eEF1--
The first of the elongation factors is composed of
eEF2--
This elongation factor is inhibited by phosphorylation
via eEF2 kinase on Thr-56 and Thr-58, the phosphorylation of the latter site requiring prior phosphorylation of the former (26, 63).
Insulin--
Insulin, by far the best characterized effector of
protein synthesis, stimulates both initiation and elongation. eIF2 Amino Acids--
Addition of amino acids to starved mammalian
cells causes many of the same modifications as insulin, but some of the
pathways appear to be different. The activity of eIF2B is increased,
partly through dephosphorylation of eIF2 GPCR--
Less is known about the regulation of protein
synthesis by GPCR per se. Angiotensin causes phosphorylation
of eIF4E (81) and PHAS-I (82), the µ-opioid receptor activates
p70S6K (83), and gastrin leads to PHAS-I phosphorylation
(84). However, much has been published on the effects of phorbol
esters, which mimic DAG, on protein synthesis. Phorbol esters cause
phosphorylation of eIF2B through GSK-3 (52), eIF4E through Mnk1 (43,
44, 59), eIF4G (85), S6 (85), and eEF1 (86). Although this pattern is
reminiscent of insulin, phorbol esters do not operate through PI3-K
(23).
Ca2+--
Changes in the level of intracellular
Ca2+ and its distribution among compartments affect protein
synthesis in at least two ways (26). Depletion of Ca2+ from
the sarcoplasmic/endoplasmic reticulum by hormones like vasopressin
inhibits initiation by phosphorylation of eIF2 Signaling pathways do not stimulate translation of all mRNAs
equally. Messenger RNAs differ widely in translational efficiency. Factors contributing to low efficiency of translation include a highly
structured 5'-UTR, the presence of upstream AUGs, and poor sequence
context for the initiating AUG (89), all of which are found in the
5'-UTRs of mRNAs for scarce proteins (90). mRNAs with these
properties encode a disproportionate share of proteins involved in cell
growth and cell cycle progression (89). These mRNAs are poorly
translated in quiescent cells but preferentially recruited to ribosomes
after a mitogenic signal (91-93). Overexpression of eIF4E in cultured
cells preferentially stimulates translation of a number of mRNAs
with high 5'-UTR secondary structure that are involved in cell growth
and division (89). Expression of cell cycle-dependent
proteins like c-Myc (64) and cyclin D (94) requires mTOR, and
inhibition of mTOR with rapamycin prolongs the G1 phase in
both T-cells (95) and yeast (96). These results suggest that pathways
which activate the unwinding machinery, i.e. by
phosphorylation of eIF4E, eIF4G, or PHAS, disproportionately stimulate
translation of growth-regulated mRNAs with high 5'-UTR secondary structure.
5'-TOP mRNAs are also differentially regulated in response to
extracellular signals (97). These encode many translational components,
including ribosomal proteins, eEF1 The insulin-stimulated pathways to general protein synthesis and to
growth-regulated protein synthesis in 32D cells can be dissected with
rapamycin (64). Insulin-stimulated total protein synthesis is inhibited
only ~10%, and actin synthesis is not affected at all, but
insulin-stimulated c-Myc synthesis is completely inhibited. Also,
expression of constitutively active PKC Protein synthesis is one of the most complicated biochemical
processes undertaken by the cell, requiring roughly 150 different polypeptides and 70 different RNAs. Yet only seven polypeptides (eIF2
![]()
INTRODUCTION
TOP
INTRODUCTION
Mechanism of Protein Synthesis
Signaling Intermediates...
Components of the Core...
Examples of Specific Signaling...
Modification of Initiation...
Conclusions and Future...
REFERENCES
![]()
Mechanism of Protein Synthesis
TOP
INTRODUCTION
Mechanism of Protein Synthesis
Signaling Intermediates...
Components of the Core...
Examples of Specific Signaling...
Modification of Initiation...
Conclusions and Future...
REFERENCES

View larger version (38K):
[in a new window]
Fig. 1.
Eukaryotic protein synthesis and sites
of action for initiation and elongation factors. Factors are
abbreviated as: 2, eIF2; 2B, eIF2B; A,
eIF4A; E, eIF4E; 4F, eIF4F; G, eIF4G,
E1, eEF1; E2, eEF2; S6, ribosomal
protein S6. Those factors shown in color are targets of the
signaling pathways in Fig. 2.
![]()
Signaling Intermediates Involved in Protein Synthesis
TOP
INTRODUCTION
Mechanism of Protein Synthesis
Signaling Intermediates...
Components of the Core...
Examples of Specific Signaling...
Modification of Initiation...
Conclusions and Future...
REFERENCES

View larger version (21K):
[in a new window]
Fig. 2.
Signaling pathways leading to
alterations in the activities or availability of protein synthesis
initiation and elongation factors.
,
1,
2,
) and is activated by both RTKs
and GPCR. In the former case, PI3-K is involved (17), but in the
latter, there are both PI3-K-dependent (18) and
-independent (19) pathways. PKB is targeted to the plasma membrane by
direct binding to PtdIns(3,4)P2 and
PtdIns(3,4,5)P3 through its PH domain (20), where it is
activated by phosphorylation at Thr-308 by PDK (15).
-
) that
differ in responsiveness to phospholipids and Ca2+ (21).
Classical PKCs (
,
, and
) are activated and eventually down-regulated by phorbol esters, which are structural analogs of the
physiological signal DAG, but atypical isoforms (
and
) are not.
Insulin activates both classical and atypical isoforms (22, 23). PKC
is activated downstream of PI3-K (24) via direct phosphorylation at
Thr-410 by PDK1 (25).
![]()
Components of the Core Translational Machinery That Are
Targets of Signaling Pathways
TOP
INTRODUCTION
Mechanism of Protein Synthesis
Signaling Intermediates...
Components of the Core...
Examples of Specific Signaling...
Modification of Initiation...
Conclusions and Future...
REFERENCES
represent cellular stress, but eIF2
phosphorylation also changes as a result of normal signaling pathways, e.g. those regulated
by amino acids (49) and interleukin-3 (50). Phosphorylation of eIF2
on Ser-51 by several different kinases causes formation of a stable
complex with eIF2B (Fig. 1), thereby reducing the concentration of
active eIF2B (51).
subunit and
inactivated by GSK-3
and -
(52). Phosphorylation occurs at
Ser-540, although evidence suggests that a priming phosphorylation at
Ser-544 by some other kinase is needed (53).
,
,
, and
subunits. Various subunits are phosphorylated
in vitro by several kinases, including casein kinase II,
multipotential S6 kinase, and PKC (36). In the latter two cases, these
phosphorylations result in a stimulation of elongation and GDP/GTP
exchange, respectively.
![]()
Examples of Specific Signaling Pathways Affecting Protein
Synthesis
TOP
INTRODUCTION
Mechanism of Protein Synthesis
Signaling Intermediates...
Components of the Core...
Examples of Specific Signaling...
Modification of Initiation...
Conclusions and Future...
REFERENCES
phosphorylation does not change, but eIF2B activity nonetheless
increases by the pathway IRS-1 (Tyr-608, -628, and -658; Ref. 64)
PI3-K (64)
PDK
PKB (65)
GSK-3 (28)
eIF2B
(53) (see
Fig. 2). However, insulin may activate eIF2B through additional routes, because constitutively active PKC
stimulates general protein synthesis in an insulin-dependent manner without activating
p70S6K, suggesting that PKB is not involved (23). Binding
of SH-PTP2 to IRS-1(Tyr-1172 and -1222) attenuates insulin-stimulated
protein synthesis (66). PHAS-I is phosphorylated in response to insulin (58, 57) through a rapamycin-sensitive but MAPK-insensitive pathway
(64, 67, 68) that includes PKB (69), indicating that the pathway is
IRS-1 (Tyr-608, -628, and -658)
PI3-K
PDK
PKB
mTOR
PHAS. Phosphorylation of eIF4E is by the pathway IRS-1 (Tyr-895)
Grb-2·SOS
Ras
Raf
MEK
ERK
Mnk. (There are
numerous other RKS that contribute to insulin stimulation of MAPK,
especially Shc.) eIF4E association with eIF4G is stimulated by insulin
(70) as is eIF4G phosphorylation (60). Insulin also stimulates
elongation by two mechanisms: phosphorylation of eEF1 and S6, the
latter occurring by both multipotential S6 kinase (36) and
p70S6K (71), and dephosphorylation of eEF2 via a
rapamycin-sensitive route (72). Other growth factors acting through
RTKs produce similar changes, e.g. platelet-derived growth
factor, nerve growth factor, and EGF (73, 74).
and partly through
phosphorylation of eIF2B
, but GSK-3 activity is not altered (75).
Like insulin, amino acids cause phosphorylation of p70S6K
and PHAS through a mTOR-dependent pathway (76-79). Unlike
insulin, however, the pathway does not involve PKB (78, 77) but does involve tRNA aminoacylation (80). The insulin- or IGF-1-mediated phosphorylation of p70S6K and PHAS-I requires amino acids
(76, 79). In the presence of insulin, amino acids activate eIF2B but
not eIF4E (75).
via PKR (87).
Elevation of cytosolic Ca2+ by agents such as bradykinin
inhibits elongation by phosphorylation of eEF2 via eEF2K (26).
Similarly, stimulation of the NMDA receptor causes eEF2 phosphorylation
(88).
![]()
Modification of Initiation Factors Can Affect the Spectrum of
mRNAs Translated
TOP
INTRODUCTION
Mechanism of Protein Synthesis
Signaling Intermediates...
Components of the Core...
Examples of Specific Signaling...
Modification of Initiation...
Conclusions and Future...
REFERENCES
, eEF2, and poly(A)-binding protein. 5'-TOP mRNAs are recruited to polysomes in a
growth-dependent fashion that is selectively inhibited by
rapamycin (72, 98). This finding alone does not distinguish between
signaling through PHAS and signaling through p70S6K,
because the pathway bifurcates downstream of mTOR (99) (see Fig. 2).
However, ectopic expression of a dominant interfering p70S6K blocks both activation of p70S6K and
5'-TOP mRNA translation, indicating a direct role for
p70S6K (61).
in the absence of IRS-1,
which bypasses the mTOR pathway, permits insulin-stimulated general
protein synthesis but not c-Myc synthesis (23). This suggests that the
insulin signal bifurcates at some point after PI3-K, one pathway
stimulating general protein synthesis through eIF2B and one stimulating
growth-regulated protein synthesis, accounting for ~10% of the
total, through eIF4E and S6. Similarly, T-cell activation causes 13%
of the pre-existing mRNAs to be recruited to ribosomes (100), and
rapamycin causes a 15% decrease in protein synthesis in activated
T-cells (95).
![]()
Conclusions and Future Directions
TOP
INTRODUCTION
Mechanism of Protein Synthesis
Signaling Intermediates...
Components of the Core...
Examples of Specific Signaling...
Modification of Initiation...
Conclusions and Future...
REFERENCES
, eIF2B
, eIF4E, eIF4G, S6, eEF1, and eEF2) have been
identified as targets for regulatory pathways to date. Early
observations that multiple initiation and elongation factors were
phosphorylated in response to a single extracellular signal (101, 102)
may have suggested unnecessary redundancy. This now seems more
comprehensible when it is realized that modification of some factors
affects the overall rate of translation whereas modification of others affects the spectrum of mRNAs translated. Understanding the
pathways for regulation of protein synthesis holds promise for novel
approaches for cancer intervention (e.g. Ref. 103),
especially if pathways leading to growth-dependent protein
synthesis can be selectively inhibited.
| |
FOOTNOTES |
|---|
* This minireview will be reprinted in the 1999 Minireview Compendium, which will be available in December, 1999. This work was supported by Grant GM20818 from the National Institute of General Medical Sciences.
To whom correspondence should be addressed: Dept. of Biochemistry
and Molecular Biology, Louisiana State University Medical Center, 1501 Kings Highway, Shreveport, LA 71130-3932. Tel.: 318-675-5161; Fax:
318-675-5180; E-mail: rrhoad@lsumc.edu.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: eIF, eukaryotic initiation factor; aa, amino acids; AC, adenylate cyclase; CaM, calmodulin; DAG, diacylglycerol; eEF, eukaryotic elongation factor; eEF2K, eEF2 kinase; EGF, epidermal growth factor; ERK, extracellular signal-regulated kinase; GEF, guanine nucleotide exchange factor; GPCR, G-protein-coupled receptors; GSK-3, glycogen synthase kinase-3; Ins, inositol; IRS, insulin receptor substrate; MAPK, mitogen-activated protein kinase; MEK, mitogen-activated protein/ERK kinase; Mnk, MAPK-interacting kinase; mTOR, mammalian target of rapamycin; p70S6K, 70-kDa ribosomal S6 kinase; p90S6K, 90-kDa ribosomal S6 kinase; PDK, PtdIns-dependent kinase; PH, pleckstrin homology; PHAS, phosphorylated, heat- and acid-stable protein; PI3-K, phosphatidylinositol 3-kinase; PKB, protein kinase B; PKC, protein kinase C; PLC, phospholipase C; PtdIns, phosphatidylinositol; RKS, receptor kinase substrates; RTK, receptor tyrosine kinase; SH2, Src homology domain 2; SH-PTP2, SH2-containing phosphotyrosine phosphatase-2; TOP, terminal oligopyrimidine; UTR, untranslated region.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Baserga, R.
(1990)
Cancer Res.
50,
6769-6771 |
| 2. | Merrick, W. C., and Hershey, J. W. B. (1996) in Translational Control (Hershey, J. W. B. , Mathews, M. B. , and Sonenberg, N., eds) , pp. 31-69, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY |
| 3. | Clark, B. F. C., Grunberg-Manago, M., Gupta, N. K., Hershey, J. W. B., Hinnebusch, A. G., Jackson, R. J., Maitra, U., Mathews, M. B., Merrick, W. C., Rhoads, R. E., Sonenberg, N., Spremulli, L., Trachsel, H., and Voorma, H. O. (1996) Biochimie (Paris) 78, 11-12[CrossRef] |
| 4. | Pestova, T. V., Borukhov, S. I., and Hellen, C. U. T. (1998) Nature 394, 854-859[CrossRef][Medline] [Order article via Infotrieve] |
| 5. | Marshall, C. J. (1995) Cell 80, 179-185[CrossRef][Medline] [Order article via Infotrieve] |
| 6. |
Vaughan, M.
(1998)
J. Biol. Chem.
273,
17297 |
| 7. | White, M. F. (1998) Mol. Cell. Biochem. 182, 3-11[CrossRef][Medline] [Order article via Infotrieve] |
| 8. |
Pluskey, S.,
Wandless, T. J.,
Walsh, C. T.,
and Shoelson, S. E.
(1995)
J. Biol. Chem.
270,
2897-2900 |
| 9. |
Vojtek, A. B.,
and Der, C. J.
(1998)
J. Biol. Chem.
273,
19925-19928 |
| 10. | Downward, J. (1998) Nature 396, 416-417[CrossRef][Medline] [Order article via Infotrieve] |
| 11. | Rodriguez-Viciana, P., Warne, P. H., Vanhaesebroeck, B., Waterfield, M. D., and Downward, J. (1996) EMBO J. 15, 2442-2451[Medline] [Order article via Infotrieve] |
| 12. | Divecha, N., and Irvine, R. F. (1995) Cell 80, 269-278[CrossRef][Medline] [Order article via Infotrieve] |
| 13. |
Bondeva, T.,
Pirola, L.,
Bulgarelli-Leva, G.,
Rubio, I.,
Wetzker, R.,
and Wymann, M. P.
(1998)
Science
282,
293-296 |
| 14. |
Vlahos, C. J.,
Matter, W. F.,
Hui, K. Y.,
and Brown, R. F.
(1994)
J. Biol. Chem.
269,
5241-5248 |
| 15. |
Stokoe, D.,
Stephens, L.,
Copeland, T.,
Gaffney, R. J.,
Reese, C. B.,
Painter, G. F.,
Holmes, A. B.,
McCormick, F.,
and Hawkins, P. T.
(1997)
Science
277,
567-570 |
| 16. |
Stephens, L.,
Anderson, K.,
Stokoe, D.,
Erdjument-Bromage, H.,
Painter, G. F.,
Holmes, A. B.,
Gaffney, R. J.,
Reese, C. B.,
McCormick, F.,
Tempst, P.,
Coadwell, J.,
and Hawkins, P. T.
(1998)
Science
279,
710-714 |
| 17. |
Wijkander, J.,
Holst, L. S.,
Rahn, T.,
Resjo, S.,
Castan, I.,
Manganiello, V.,
Belfrage, P.,
and Degerman, E.
(1997)
J. Biol. Chem.
272,
21520-21526 |
| 18. |
Murga, C.,
Laguinge, L.,
Wetzker, R.,
Cuadrado, A.,
and Gutkind, J. S.
(1998)
J. Biol. Chem.
273,
19080-19085 |
| 19. |
Moule, S. K.,
Welsh, G. I.,
Edgell, N. J.,
Foulstone, E. J.,
Proud, C. G.,
and Denton, R. M.
(1997)
J. Biol. Chem.
272,
7713-7719 |
| 20. |
Sable, C. L.,
Filippa, N.,
Filloux, C.,
Hemmings, B. A.,
and Obberghen, E. V.
(1998)
J. Biol. Chem.
273,
29600-29606 |
| 21. | Dekker, L. V., and Parker, P. J. (1994) Trends Biochem. Sci. 19, 73-77[CrossRef][Medline] [Order article via Infotrieve] |
| 22. |
Bandyopadhyay, G.,
Standaer, M. L.,
Zhao, L., Yu, B.,
Avignon, A.,
Galloway, L.,
Karnam, P.,
Moscat, J.,
and Farese, R. V.
(1997)
J. Biol. Chem.
272,
2551-2558 |
| 23. | Mendez, R., Kollmorgen, G., White, M. F., and Rhoads, R. E. (1997) Mol. Cell. Biol. 17, 5184-5192[Abstract] |
| 24. |
Herrera-Velit, P.,
Knutson, K. L.,
and Reiner, N. E.
(1997)
J. Biol. Chem.
272,
16445-16452 |
| 25. |
Le Good, J. A.,
Ziegler, W. H.,
Parekh, D. B.,
Allessi, D. R.,
Cohen, P.,
and Parker, P. J.
(1998)
Science
281,
2042-2045 |
| 26. | Nairn, A., and Palfrey, H. C. (1996) in Translational Control (Hershey, J. W. B. , Mathews, M. B. , and Sonenberg, N., eds) , pp. 295-318, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY |
| 27. | Cross, D. A. E., Allessi, D. R., Cohen, P., Andjelkovich, M., and Hemmings, B. A. (1995) Nature 378, 785-789[CrossRef][Medline] [Order article via Infotrieve] |
| 28. | Hajduch, E., Alessi, D. R., Hemmings, B. A., and Hundal, H. S. (1998) Diabetes 47, 1006-1013[Abstract] |
| 29. |
van Weeren, P. C.,
Bruyn, M. T.,
de Vries-Smits, M. M.,
van Lint, J.,
and Burgering, B. M.
(1998)
J. Biol. Chem.
273,
13150-13156 |
| 30. |
Scott, P. H.,
Brunn, G. J.,
Kohn, R. A.,
and Lawrence, J. C.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
7772-7777 |
| 31. | Abraham, R. T., and Wiederrecht, G. J. (1996) Annu. Rev. Immunol. 14, 483-510[CrossRef][Medline] [Order article via Infotrieve] |
| 32. |
Scott, P. H.,
and Lawrence, J. C.
(1998)
J. Biol. Chem.
273,
34496-34501 |
| 33. | Proud, C. G. (1996) Trends Biochem. Sci. 21, 181-185[CrossRef][Medline] [Order article via Infotrieve] |
| 34. |
Burnett, P. E.,
Barrow, R. K.,
Cohen, N. A.,
Snyder, S. H.,
and Sabatini, D. M.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
1432-1437 |
| 35. |
Pullen, N.,
Dennis, P. B.,
Andjelkovic, M.,
Dufner, A.,
Kozma, S. C.,
Hemmings, B. A.,
and Thomas, G.
(1998)
Science
279,
707-710 |
| 36. |
Chang, Y. W.,
and Traugh, J. A.
(1997)
J. Biol. Chem.
272,
28252-28257 |
| 37. |
Smith, J. A.,
Poteet-Smith, C. E.,
Malarkey, K.,
and Sturgill, T. W.
(1999)
J. Biol. Chem.
274,
2893-2898 |
| 38. | Shima, H., Pende, M., Chen, Y., Fumagalli, S., Thomas, G., and Kozma, S. C. (1998) EMBO J. 17, 6649-6659[CrossRef][Medline] [Order article via Infotrieve] |
| 39. |
New, L.,
Zhao, M.,
Li, Y.,
Bassett, W. W.,
Feng, Y.,
Ludwig, S.,
Padova, F. D.,
Gram, H.,
and Han, J.
(1999)
J. Biol. Chem.
274,
1026-1032 |
| 40. | Lawrence, J. C., and Abraham, R. T. (1997) Trends Biochem. Sci. 22, 345-349[CrossRef][Medline] [Order article via Infotrieve] |
| 41. |
Poulin, F.,
Gingras, A. C.,
Olsen, H.,
Chevalier, S.,
and Sonenberg, N.
(1998)
J. Biol. Chem.
273,
14002-14007 |
| 42. |
Brunn, G. J.,
Hudson, C. C.,
Sekulic, A.,
Williams, J. M.,
Hosoi, H.,
Houghton, P. J.,
Lawrence, J. C.,
and Abraham, R. T.
(1997)
Science
277,
99-101 |
| 43. | Waskiewicz, A. J., Flynn, A., Proud, C. G., and Cooper, J. A. (1997) EMBO J. 16, 1909-1920[CrossRef][Medline] [Order article via Infotrieve] |
| 44. | Fukunaga, R., and Hunter, T. (1997) EMBO J. 16, 1921-1933[CrossRef][Medline] [Order article via Infotrieve] |
| 45. |
Waskiewicz, A. J.,
Johnson, J. C.,
Penn, B.,
Mahalingam, M.,
Kimball, S. R.,
and Cooper, J. A.
(1999)
Mol. Cell. Biol.
19,
1871-1880 |
| 46. | Pyronnet, S., Imataka, H., Gingras, A.-C., Fukunaga, R., Hunter, T., and Sonenberg, N. (1999) EMBO J. 18, 270-279[CrossRef][Medline] [Order article via Infotrieve] |
| 47. |
Redpath, N. T.,
Price, N. T.,
and Proud, C. G.
(1996)
J. Biol. Chem.
271,
17547-17554 |
| 48. | Diggle, T. A., Redpath, N. T., Heesom, K. J., and Denton, R. M. (1998) Biochem. J. 336, 525-529 |
| 49. |
Hinnebusch, A. G.
(1997)
J. Biol. Chem.
272,
21661-21664 |
| 50. |
Ito, T.,
Jagus, R.,
and May, W. S.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
7455-7459 |
| 51. | Clemens, M. J. (1996) in Translational Control (Hershey, J. W. B. , Mathews, M. B. , and Sonenberg, N., eds) , pp. 139-172, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY |
| 52. |
Welsh, G. I.,
Miyamoto, S.,
Price, N. T.,
Safer, B.,
and Proud, C. G.
(1996)
J. Biol. Chem.
271,
11410-11413 |
| 53. | Welsh, G. I., Loughlin, A. J., Foulstone, E. J., Price, N. T., and Proud, C. G. (1997) Biochem. Soc. Trans. 25 (suppl.), 191 |
| 54. |
Joshi, B.,
Cai, A.-L.,
Keiper, B. D.,
Minich, W. B.,
Mendez, R.,
Beach, C. M.,
Stepinski, J.,
Stolarski, R.,
Darzynkiewicz, E.,
and Rhoads, R. E.
(1995)
J. Biol. Chem.
270,
14597-14603 |
| 55. |
Flynn, A.,
and Proud, C. G.
(1995)
J. Biol. Chem.
270,
21684-21688 |
| 56. |
Minich, W. B.,
Balasta, M. L.,
Goss, D. J.,
and Rhoads, R. E.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
7668-7672 |
| 57. |
Lin, T.,
Kong, X.,
Haystead, T. A. J.,
Pause, A.,
Belsham, G.,
Sonenberg, N.,
and Lawrence, J. C.
(1994)
Science
266,
653-656 |
| 58. | Pause, A., Belsham, G. J., Gingras, A., Donze, O., Lin, T., Lawrence, J. C., and Sonenberg, N. (1994) Nature 371, 762-767[CrossRef][Medline] [Order article via Infotrieve] |
| 59. |
Wang, X.,
Flynn, A.,
Waskiewicz, A. J.,
Webb, B. L. J.,
Vries, R. G.,
Baines, I. A.,
Cooper, J. A.,
and Proud, C. G.
(1998)
J. Biol. Chem.
273,
9373-9377 |
| 60. |
Morley, S. J.,
Dever, T. E.,
Etchison, D.,
and Traugh, J. A.
(1991)
J. Biol. Chem.
266,
4669-4672 |
| 61. | Jefferies, B. J., Fumagalli, S., Dennis, P. B., Reinhard, C., Pearson, R. B., and Thomas, G. (1997) EMBO J. 16, 3693-3704[CrossRef][Medline] [Order article via Infotrieve] |
| 62. |
Chiaberge, S.,
Cassarino, E.,
and Mangiarotti, G.
(1998)
J. Biol. Chem.
273,
27070-27075 |
| 63. | Redpath, N. T., Price, N. T., Severinov, K. V., and Proud, C. G. (1993) Eur. J. Biochem. 213, 689-699[Medline] [Order article via Infotrieve] |
| 64. | Mendez, R., Myers, M. G., White, M. F., and Rhoads, R. E. (1996) Mol. Cell. Biol. 16, 2857-2864[Abstract] |
| 65. |
Kitamura, T.,
Ogawa, W.,
Sakaue, H.,
Hino, Y.,
Kuroda, S.,
Takata, M.,
Matsumoto, M.,
Maeda, T.,
Konishi, H.,
Kikkawa, U.,
and Masuga, M.
(1998)
Mol. Cell. Biol.
18,
3708-3717 |
| 66. |
Myers, M. G.,
Mendez, R.,
Shi, P.,
Pierce, J. H.,
Rhoads, R.,
and White, M. W.
(1998)
J. Biol. Chem.
273,
26908-26914 |
| 67. | Azpiazu, I., Saltiel, A. R., DePaoli-Roach, A. A., and Lawrence, J. C. (1996) J. Biol. Chem. 27, 5033-5039 |
| 68. |
von Manteuffel, S. R.,
Gingras, A.-C.,
Ming, X.-F.,
Sonenberg, N.,
and Thomas, G.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
4076-4080 |
| 69. |
Gingras, A.-C.,
Kennedy, S. G.,
O'Leary, M. A.,
Sonenberg, N.,
and Hay, N.
(1998)
Genes Dev.
12,
502-513 |
| 70. | Sinaud, S., Balage, M., Bayle, G., Dardevet, D., Vary, T. C., Kimball, S. R., Jefferson, L. S., and Grizard, J. (1999) Am. J. Physiol. 39, E50-E61 |
| 71. |
Myers, M. G.,
Grammer, T. C.,
Wang, L.,
Sun, X. J.,
Pierce, J. H.,
Blenis, J.,
and White, M. F.
(1994)
J. Biol. Chem.
269,
28783-28789 |
| 72. | Redpath, N. T., Foulstone, E. J., and Proud, C. G. (1996) EMBO J. 15, 2291-2297[Medline] [Order article via Infotrieve] |
| 73. |
Kleijn, M.,
Welsh, G. I.,
Scheper, G. C.,
Voorma, H. O.,
Proud, C. G.,
and Thomas, A. A. M.
(1998)
J. Biol. Chem.
273,
5536-5541 |
| 74. |
Fraser, C. S.,
Pain, V.,
and Morley, S. J.
(1999)
J. Biol. Chem.
274,
196-204 |
| 75. |
Kimball, S. R.,
Horetsky, R. L.,
and Jefferson, L. S.
(1998)
J. Biol. Chem.
273,
30945-30953 |
| 76. |
Xu, G.,
Kwon, G.,
Marshall, C. A.,
Lin, T.-A.,
Lawrence, J. C., Jr.,
and McDaniel, M. L.
(1998)
J. Biol. Chem.
273,
28178-28184 |
| 77. | Wang, X., Campbell, L. E., Miller, C. M., and Proud, C. G. (1998) Biochem. J. 334, 261-267 |
| 78. |
Hara, K.,
Yonezawa, K.,
Weng, Q. P.,
Kozlowski, M. T.,
Belham, C.,
and Avruch, J.
(1998)
J. Biol. Chem.
273,
14484-14494 |
| 79. |
Shigemitsu, K.,
Tsujishita, Y.,
Hara, K.,
Nanahoshi, M.,
Avruch, J.,
and Yonezawa, K.
(1999)
J. Biol. Chem.
274,
1058-1065 |
| 80. |
Iiboshi, Y.,
Pabst, P. J.,
Kawasome, H.,
Hosoi, H.,
Abraham, R. T.,
Houghton, P. J.,
and Terada, N.
(1999)
J. Biol. Chem.
274,
1092-1099 |
| 81. |
Rao, G. N.,
Griendling, K. K.,
Frederickson, R. M.,
Sonenberg, N.,
and Alexander, R. W.
(1994)
J. Biol. Chem.
269,
7180-7184 |
| 82. |
Fleurent, M.,
Gingras, A.-C.,
Sonenberg, N.,
and Meloche, S.
(1997)
J. Biol. Chem.
272,
4006-4012 |
| 83. |
Polakiewicz, R. D.,
Schiefer, S. M.,
Gingras, A. C.,
Sonenberg, N.,
and Comb, M. J.
(1998)
J. Biol. Chem.
273,
23534-23541 |
| 84. | Pyronnet, S., Gingras, A.-C., Bouisson, M., Kowalski-Chauvel, A., Seva, C., Vaysse, N., Sonenberg, N., and Pradayrol, L. (1998) Oncogene 16, 2219-2227[CrossRef][Medline] [Order article via Infotrieve] |
| 85. |
Morley, S. J.,
and Traugh, J. A.
(1990)
J. Biol. Chem.
265,
10611-10616 |
| 86. |
Venema, R. C.,
Peters, H. I.,
and Traugh, J. A.
(1991)
J. Biol. Chem.
266,
12574-12580 |
| 87. |
Reilly, B. A.,
Brostrom, M. A.,
and Brostrom, C. O.
(1998)
J. Biol. Chem.
273,
3747-3755 |
| 88. | Scheetz, A. J., Nairn, A. C., and Constantine-Paton, M. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 14771-14775 |
| 89. | De Benedetti, A., and Harris, A. L. (1999) Int. J. Biochem. Cell Biol. 31, 59-72[CrossRef][Medline] [Order article via Infotrieve] |
| 90. | Kochetov, A. V., Ischenko, I. V., Vorobiev, D. G., Kel, A. E., Babenko, V. N., Kisselev, L. L., and Kolchanov, N. A. (1998) FEBS Lett. 440, 351-355[CrossRef][Medline] [Order article via Infotrieve] |
| 91. |
Darveau, A.,
Pelletier, J.,
and Sonenberg, N.
(1985)
Proc. Natl. Acad. Sci. U. S. A.
82,
2315-2319 |
| 92. |
Manzella, J. M.,
Rychlik, W.,
Rhoads, R. E.,
Hershey, J. W. B.,
and Blackshear, P. J.
(1991)
J. Biol. Chem.
266,
2383-2389 |
| 93. | Nielsen, F. C., Ostergaard, L., Nielsen, J., and Christiansen, J. (1995) Nature 377, 358-362[CrossRef][Medline] [Order article via Infotrieve] |
| 94. |
Muise-Helmericks, R. C.,
Grimes, H. L.,
Bellacosa, A.,
Malstrom, S. E.,
Tsichlis, P. N.,
and Rosen, N.
(1998)
J. Biol. Chem.
273,
29864-29872 |
| 95. | Terada, N., Takase, K., Pabst, P., Nairn, A. C., and Gelfand, E. W. (1995) J. Immunol. 155, 3418-3426[Abstract] |
| 96. | Barbet, N. C., Schneider, U., Helliwell, S. B., Stansfield, I., Tuite, M. F., and Hall, M. N. (1996) Mol. Biol. Cell 7, 25-42[Abstract] |
| 97. |
Hornstein, E.,
Git, A.,
Braunstein, I.,
Avnil, D.,
and Meyuhas, O.
(1999)
J. Biol. Chem.
274,
1708-1714 |
| 98. |
Jefferies, H. B. J.,
Reinhard, C.,
Kozma, S. C.,
and Thomas, G.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
4441-4445 |
| 99. | von Manteuffel, S., Dennis, P. B., Pullen, N., Gingras, A., Sonenberg, N., and Thomas, G. (1997) Mol. Cell. Biol. 17, 5426-5436[Abstract] |
| 100. |
Garcia-Sanz, J. A.,
Mikulits, W.,
Livingstone, A.,
Lefkovits, I.,
and Mullner, E. W.
(1998)
FASEB J.
12,
299-306 |
| 101. |
Duncan, R.,
and Hershey, J. W. B.
(1985)
J. Biol. Chem.
260,
5493-5497 |
| 102. |
Morley, S. J.,
and Traugh, J. A.
(1989)
J. Biol. Chem.
264,
2401-2404 |
| 103. |
Aktas, H.,
Fluckiger, R.,
Acosta, J. A.,
Savage, J. M.,
Palakurthi, S. S.,
and Halperin, J. A.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
8280-8285 |
This article has been cited by other articles:
![]() |
R. J. Southgate, B. Neill, O. Prelovsek, A. El-Osta, Y. Kamei, S. Miura, O. Ezaki, T. J. McLoughlin, W. Zhang, T. G. Unterman, et al. FOXO1 Regulates the Expression of 4E-BP1 and Inhibits mTOR Signaling in Mammalian Skeletal Muscle J. Biol. Chem., July 20, 2007; 282(29): 21176 - 21186. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Dogra, H. Changotra, N. Wedhas, X. Qin, J. E. Wergedal, and A. Kumar TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine FASEB J, June 1, 2007; 21(8): 1857 - 1869. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Leger, R. Cartoni, M. Praz, S. Lamon, O. Deriaz, A. Crettenand, C. Gobelet, P. Rohmer, M. Konzelmann, F. Luthi, et al. Akt signalling through GSK-3{beta}, mTOR and Foxo1 is involved in human skeletal muscle hypertrophy and atrophy J. Physiol., November 1, 2006; 576(3): 923 - 933. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Utsuki, Q.-s. Yu, D. Davidson, D. Chen, H. W. Holloway, A. Brossi, K. Sambamurti, D. K. Lahiri, N. H. Greig, and T. Giordano Identification of Novel Small Molecule Inhibitors of Amyloid Precursor Protein Synthesis as a Route to Lower Alzheimer's Disease Amyloid-beta Peptide J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 855 - 862. [Abstract] [Full Text] [PDF] |
||||
![]() |
J Malta-Vacas, C Aires, P Costa, A R Conde, S Ramos, A P Martins, C Monteiro, and M Brito Differential expression of the eukaryotic release factor 3 (eRF3/GSPT1) according to gastric cancer histological types J. Clin. Pathol., June 1, 2005; 58(6): 621 - 625. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Shi, A. Sharma, H. Wu, A. Lichtenstein, and J. Gera Cyclin D1 and c-myc Internal Ribosome Entry Site (IRES)-dependent Translation Is Regulated by AKT Activity and Enhanced by Rapamycin through a p38 MAPK- and ERK-dependent Pathway J. Biol. Chem., March 25, 2005; 280(12): 10964 - 10973. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. L. Korneeva, E. A. First, C. A. Benoit, and R. E. Rhoads Interaction between the NH2-terminal Domain of eIF4A and the Central Domain of eIF4G Modulates RNA-stimulated ATPase Activity J. Biol. Chem., January 21, 2005; 280(3): 1872 - 1881. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. D. Dinkova, B. D. Keiper, N. L. Korneeva, E. J. Aamodt, and R. E. Rhoads Translation of a Small Subset of Caenorhabditis elegans mRNAs Is Dependent on a Specific Eukaryotic Translation Initiation Factor 4E Isoform Mol. Cell. Biol., January 1, 2005; 25(1): 100 - 113. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. GRUDZIEN, J. STEPINSKI, M. JANKOWSKA-ANYSZKA, R. STOLARSKI, E. DARZYNKIEWICZ, and R. E. RHOADS Novel cap analogs for in vitro synthesis of mRNAs with high translational efficiency RNA, September 1, 2004; 10(9): 1479 - 1487. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Halayko, S. Kartha, G. L. Stelmack, J. McConville, J. Tam, B. Camoretti-Mercado, S. M. Forsythe, M. B. Hershenson, and J. Solway Phophatidylinositol-3 Kinase/Mammalian Target of Rapamycin/p70S6K Regulates Contractile Protein Accumulation in Airway Myocyte Differentiation Am. J. Respir. Cell Mol. Biol., September 1, 2004; 31(3): 266 - 275. [Abstract] [Full Text] [PDF] |
||||
![]() |